Category
ANTI-CANCER API
ANTI-CANCER API
Consistent
Purity
Global-Ready
Molecules
Advanced
Manufacturing
Scalable
Production
Partnership
Support
Abiraterone Acetate API has been developed by ASANA Pharmaceutical as part of its expanding oncology portfolio. Abiraterone Acetate API, identified by CAS number 154229-18-2, is a key hormonal therapy used in the treatment of metastatic prostate cancer.
ASANA Pharmaceutical brings deep specialization in the development and manufacturing of high-purity oncology APIs like Abiraterone Acetate. With emphasis on complex synthesis and stringent quality control, ASANA delivers therapeutic actives that meet international regulatory standards. Our facilities are designed to serve partners across North America, Europe, and Asia, ensuring consistent output and product reliability for critical cancer treatments.
ASANA Pharmaceutical operates in synergy with global development and formulation partners, leveraging expertise in oncology research, process engineering, regulatory documentation, and analytical validation to lead in the anti-cancer API segment. With Abiraterone Acetate [CAS No. 154229-18-2] as a core molecule in its hormone therapy portfolio, ASANA supports therapies that address prostate cancer through androgen biosynthesis inhibition. As demand for advanced oncology APIs continues to grow, ASANA is committed to delivering:
Abiraterone Acetate API are available on public databases such as Wikipidia!